Preclinical studies in animals and human clinical trials question whether the endothelial glycocalyx layer is a clinically important permeability barrier. Glycocalyx breakdown products in plasma mostly originate from 99.6–99.8% of the endothelial surface not involved in transendothelial passage of water and proteins. Fragment concentrations correlate poorly with in vivo imaging of glycocalyx thickness, and calculations of expected glycocalyx resistance are incompatible with measured hydraulic conductivity values. Increases in plasma breakdown products in rats did not correlate with vascular permeability. Clinically, three studies in humans show inverse correlations between glycocalyx degradation products and the capillary leakage of albumin and fluid.

中文翻译：

---

糖萼作为渗透屏障：基础科学和临床证据

动物临床前研究和人体临床试验质疑内皮糖萼层是否是临床上重要的渗透屏障。血浆中的糖萼分解产物主要来自 99.6-99.8% 的内皮表面，不参与水和蛋白质的跨内皮通道。片段浓度与糖萼厚度的体内成像相关性很差，预期糖萼阻力的计算与测量的水力传导率值不相容。大鼠血浆分解产物的增加与血管通透性无关。在临床上，三项人体研究表明糖萼降解产物与白蛋白和液体的毛细血管渗漏之间呈负相关。